KALA
KALA BIO, Inc.
1W: -18.7%
1M: -50.5%
3M: -64.9%
YTD: -67.8%
1Y: -97.0%
3Y: -98.7%
5Y: -100.0%
$0.17
-0.03 (-12.60%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.4M
52W Range0.2-20.6
Volume2,094,802
Avg Volume7,102,833
Beta-2.37
Dividend—
Analyst Ratings
Company Info
CEOAvi Minkowitz
Employees38
SectorHealthcare
IndustryBiotechnology
IPO Date2017-07-20
Websitekalarx.com
1167 Massachusetts Avenue
Arlington, MA 02476
US
Arlington, MA 02476
US
781 996 5252
About KALA BIO, Inc.
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Latest News
12 Health Care Stocks Moving In Thursday's Intraday Session
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Crude Oil Gains Over 5%; US Inflation Holds Steady At 2.4%
US Stocks Mixed; Dow Falls 300 Points
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Purdy Brendan P. | 0 | — | 2026-01-30 | |
| Posen Hillel D. | 0 | — | 2026-01-30 | |
| Minkowitz Avraham | 0 | — | 2026-01-30 | |
| Colman Yonatan C. | 0 | — | 2026-01-30 | |
| Berger Chaim D. | 0 | — | 2026-01-30 |